Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2024
Epigenome Reprogramming Through H3K27 and H3K4 Trimethylation as a Resistance Mechanism to DNA Methylation Inhibition in BRAFV600E-Mutated Colorectal CancerHey Min Lee, Ajay Kumar Saw, Van K Morris, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 9, 2022
Resistance Mechanisms to Anti-Epidermal Growth Factor Receptor Therapy in RAS/RAF Wild-Type Colorectal Cancer Vary by Regimen and Line of TherapyChristine M Parseghian, Ryan Sun, Melanie Woods, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 11, 2023
Antitumor Efficacy of Dual Blockade with Encorafenib + Cetuximab in Combination with Chemotherapy in Human BRAFV600E-Mutant Colorectal CancerStefania Napolitano, Melanie Woods, Hey Min Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2025
Results of the Phase I/II Study and Preliminary B-cell Gene Signature of Combined Inhibition of Glutamine Metabolism and EGFR in Colorectal CancerKristen K Ciombor, Seong-Woo Bae, Jennifer G Whisenant, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 28, 2020
Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)Scott Kopetz, Katherine A Guthrie, Van K Morris, et al.
Biorxiv : the Preprint Server for Biology|February 3, 2025
Adaptive Plasticity Tumor Cells Modulate MAPK-Targeting Therapy Response in Colorectal CancerOscar E Villarreal, Yixin Xu, Ha Tran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2026
Reprogramming of Cellular Plasticity via ETS and MYC Core-regulatory Circuits During Response to MAPK Inhibition in BRAF-mutant Colorectal CancerHey Min Lee, Zhao Zheng, Alexey Sorokin, et al.
Biorxiv : the Preprint Server for Biology|February 7, 2023
Combined KRASG12C and SOS1 inhibition enhances and extends the anti-tumor response in KRASG12C-driven cancers by addressing intrinsic and acquired resistanceVenu Thatikonda, Hengyu Lu, Sabine Jurado, et al.
Cell Reports. Medicine|July 27, 2025
Therapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancersMadelaine S Theardy, Mitsunobu Takeda, Alexey Sorokin, et al.
Biorxiv : the Preprint Server for Biology|July 4, 2025
Reprogramming of Cellular Plasticity via ETS and MYC Core-regulatory Circuits During Response to MAPK Inhibition in BRAF-mutant Colorectal CancerHey Min Lee, Zhao Zheng, Alexey Sorokin, et al.
Pageof 3